BRAF mutation at V600E is present in 40-60% of cutaneous melanomas and can be treated with BRAF inhibitor (BRAFi) (vemurafenib or dabrafenib) [1, 2] or combined BRAFi and MEK inhibitor (MEKi). Here, BRAF is linked to cutaneous melanoma.